Status:
COMPLETED
Dapagliflozin in Type 2 Diabetes Patients, a Retrospective Cohort Study From Turkey
Lead Sponsor:
AstraZeneca Turkey
Collaborating Sponsors:
Optimum Contract Research Organization, Turkey
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-75 years
Brief Summary
Background/Rationale: Objectives and Hypotheses: To describe characteristics of patients with type 2 diabetes (T2D) prescribed dapagliflozin in routine internal medicine and endocrinology outpatient ...
Detailed Description
This study is a descriptive retrospective observational cohort study using data from Turkish patient medical records from 81 different internal medicine and/or endocrinology clinics across the whole c...
Eligibility Criteria
Inclusion
- Age ≥18 and ≤75 years at index date.
- First prescription for dapagliflozin between July 2016 and Aug 2017
- Minimum 6 months of registration in the centres at the index date
- Established Type 2 diabetes prior to the index date
Exclusion
- Patients with Type 1 diabetes
- Patients with gestational diabetes
- Being included in another interventional clinical trial at between index date and enrollment date
- Estimated Glomerular Filtration Rate \< 30 ml/min
Key Trial Info
Start Date :
May 24 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2018
Estimated Enrollment :
1683 Patients enrolled
Trial Details
Trial ID
NCT03407196
Start Date
May 24 2017
End Date
February 28 2018
Last Update
March 7 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Keçiören Training and Research Hospital
Ankara, Turkey (Türkiye), 06280